Key Points
- Insider sale: Xencor VP John Desjarlais sold 73,367 shares on December 19 at an average of $15.72 for $1,153,329.24, reducing his stake by 23.67% to 236,574 shares (valued at ~$3.72M).
- Mixed quarterly results: Xencor beat EPS estimates (‑$0.08 vs. ‑$0.72) but missed revenue expectations ($21.0M vs. $29.73M), with revenue up 18% year‑over‑year while the company remains unprofitable with negative net margin and ROE.
- Analyst view: The consensus is a "Moderate Buy" with an average price target of $24.88 after several upgrades and outperforms, though one firm (Weiss Ratings) retains a sell rating.
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) VP John Desjarlais sold 73,367 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president directly owned 236,574 shares in the company, valued at $3,718,943.28. This represents a 23.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Xencor Trading Down 1.5%
NASDAQ:XNCR opened at $15.22 on Friday. The stock has a 50 day moving average of $15.51 and a 200-day moving average of $11.44. The firm has a market capitalization of $1.09 billion, a PE ratio of -8.60 and a beta of 0.96. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $24.88.
Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.64. The business had revenue of $21.00 million during the quarter, compared to analyst estimates of $29.73 million. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The business's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.71) EPS. As a group, analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
XNCR has been the topic of a number of analyst reports. Cantor Fitzgerald increased their price objective on shares of Xencor from $40.00 to $42.00 and gave the stock an "overweight" rating in a report on Thursday, November 6th. Truist Financial initiated coverage on shares of Xencor in a research note on Monday, November 24th. They issued a "buy" rating and a $29.00 price target on the stock. Royal Bank Of Canada lifted their price target on Xencor from $18.00 to $19.00 and gave the company an "outperform" rating in a report on Thursday, November 6th. Wedbush reissued an "outperform" rating and issued a $26.00 price objective on shares of Xencor in a report on Thursday, November 6th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a research report on Monday, December 22nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Xencor has an average rating of "Moderate Buy" and a consensus price target of $24.88.
Get Our Latest Analysis on Xencor
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Amalgamated Bank raised its position in Xencor by 4.8% in the third quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 947 shares in the last quarter. HighVista Strategies LLC grew its stake in shares of Xencor by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company's stock worth $262,000 after purchasing an additional 1,362 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 1,449 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Xencor by 9.1% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,272 shares of the biopharmaceutical company's stock worth $144,000 after purchasing an additional 1,525 shares in the last quarter. Finally, State of Tennessee Department of Treasury lifted its stake in Xencor by 6.2% during the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company's stock valued at $241,000 after purchasing an additional 1,784 shares during the last quarter.
About Xencor
(
Get Free Report)
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
